LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS vs MEDROXYPROGESTERONE ACETATE

Compare LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS (Hormone) and MEDROXYPROGESTERONE ACETATE (MEDROXYPROGESTERONE ACETATE) — clinical data, side effects, and patient experiences.

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS

· Hormone

How it works

12.1 Mechanism of Action COCs prevent pregnancy primarily by suppressing ovulation.

Approved for

1 INDICATIONS AND USAGE Introvale is indicated for use by females of reproductive potential to prevent pregnancy. Introvale is a combination of levonorgestrel

a progestin

and ethinyl estradiol

an estrogen

OralTablet

MEDROXYPROGESTERONE ACETATE

MEDROXYPROGESTERONE ACETATE · Hormone

How it works

12.1 Mechanism of Action Medroxyprogesterone acetate (MPA) injectable suspension, inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulati...

Approved for

longer than 2 years) birth control method unless other options are considered inadequate. (1

5.1)

IntramuscularTablet

Quick Comparison

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETSMEDROXYPROGESTERONE ACETATE

Drug Class

Hormone

Route

Oral

Intramuscular

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS

Nausea

0.1-1%

Abdominal Pain

0.1-1%

Drug Not Working

0.1-1%

Headache

0.1-1%

MEDROXYPROGESTERONE ACETATE

Drug Not Working

0.1-1%

Nausea

0.1-1%

Headache

0.1-1%

Depression

0.1-1%

Fatigue

0.1-1%

Anxiety

0.1-1%

Weight Gain

0.1-1%

Dizziness

0.1-1%

FDA Warnings

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS

5 WARNINGS AND PRECAUTIONS Vascular risks: Stop if a thrombotic or thromboembolic event occurs
Consider cardiovascular risk factors before initiating in all females, particularly those over 35 years
If feasible, stop levonorgestrel and ethinyl estradiol tablets at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism
The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the likelihood of ovulation increases after the third postpartum week

MEDROXYPROGESTERONE ACETATE

5 WARNINGS AND PRECAUTIONS Thromboembolic Disorders: Discontinue medroxyprogesterone acetate injectable suspension in patients who develop thrombosis
2 ) Cancer Risks: Monitor women with a strong family history of breast cancer carefully
It is unknown if use of medroxyprogesterone acetate injectable suspension by younger women will reduce peak bone mass and increase the risk for osteoporotic fracture in later life
Other birth control methods should be considered in the risk/benefit analysis for the use of medroxyprogesterone acetate injectable suspension in women with osteoporosis risk factors

Clinical Trial Data

No head-to-head clinical studies found for LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS vs MEDROXYPROGESTERONE ACETATE.

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS vs MEDROXYPROGESTERONE ACETATE: What You Should Know

Key Differences

Both LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS and MEDROXYPROGESTERONE ACETATE belong to the Hormone class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS is administered via Oral, whereas MEDROXYPROGESTERONE ACETATE uses Intramuscular. Route of administration can affect onset of action and patient adherence.

Safety Considerations

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS carries 4 FDA warnings. MEDROXYPROGESTERONE ACETATE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

LEVONORGESTREL AND ETHINYL ESTRADIOL vs LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS→LEVONORGESTREL AND ETHINYL ESTRADIOL vs MEDROXYPROGESTERONE ACETATE→LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS vs NORGESTIMATE AND ETHINYL ESTRADIOL→MEDROXYPROGESTERONE ACETATE vs NORGESTIMATE AND ETHINYL ESTRADIOL→ESTRADIOL VALERATE AND ESTRADIOL VALERATE vs LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS→ESTRADIOL VALERATE AND ESTRADIOL VALERATE vs MEDROXYPROGESTERONE ACETATE→

Loading comparison data...

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS vs MEDROXYPROGESTERONE ACETATE

Compare LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS (Hormone) and MEDROXYPROGESTERONE ACETATE (MEDROXYPROGESTERONE ACETATE) — clinical data, side effects, and patient experiences.

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS

· Hormone

How it works

12.1 Mechanism of Action COCs prevent pregnancy primarily by suppressing ovulation.

Approved for

1 INDICATIONS AND USAGE Introvale is indicated for use by females of reproductive potential to prevent pregnancy. Introvale is a combination of levonorgestrel

a progestin

and ethinyl estradiol

an estrogen

OralTablet

MEDROXYPROGESTERONE ACETATE

MEDROXYPROGESTERONE ACETATE · Hormone

How it works

12.1 Mechanism of Action Medroxyprogesterone acetate (MPA) injectable suspension, inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulati...

Approved for

longer than 2 years) birth control method unless other options are considered inadequate. (1

5.1)

IntramuscularTablet

Quick Comparison

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETSMEDROXYPROGESTERONE ACETATE

Drug Class

Hormone

Route

Oral

Intramuscular

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS

Nausea

0.1-1%

Abdominal Pain

0.1-1%

Drug Not Working

0.1-1%

Headache

0.1-1%

MEDROXYPROGESTERONE ACETATE

Drug Not Working

0.1-1%

Nausea

0.1-1%

Headache

0.1-1%

Depression

0.1-1%

Fatigue

0.1-1%

Anxiety

0.1-1%

Weight Gain

0.1-1%

Dizziness

0.1-1%

FDA Warnings

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS

5 WARNINGS AND PRECAUTIONS Vascular risks: Stop if a thrombotic or thromboembolic event occurs
Consider cardiovascular risk factors before initiating in all females, particularly those over 35 years
If feasible, stop levonorgestrel and ethinyl estradiol tablets at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism
The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the likelihood of ovulation increases after the third postpartum week

MEDROXYPROGESTERONE ACETATE

5 WARNINGS AND PRECAUTIONS Thromboembolic Disorders: Discontinue medroxyprogesterone acetate injectable suspension in patients who develop thrombosis
2 ) Cancer Risks: Monitor women with a strong family history of breast cancer carefully
It is unknown if use of medroxyprogesterone acetate injectable suspension by younger women will reduce peak bone mass and increase the risk for osteoporotic fracture in later life
Other birth control methods should be considered in the risk/benefit analysis for the use of medroxyprogesterone acetate injectable suspension in women with osteoporosis risk factors

Clinical Trial Data

No head-to-head clinical studies found for LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS vs MEDROXYPROGESTERONE ACETATE.

LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS vs MEDROXYPROGESTERONE ACETATE: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.